• 400+
    Pharmaceutical Partners
  • 150+
    Biomarker Assays
  • 300+
    Method Validations
  • 40+
    CDx

Clinical Testing

Patient Testing for Precision Medicine

  • Pan solid tumor
    Meet the diverse demands from clinicians and patients, MEDx Translational Medicine (MEDx) has developed a series of solid tumor tests, including pan-cancer gene panel tests, single cancer gene panel assays, and immunohistochemistry (IHC).
  • Hematologic Malignancy
    Most recently, molecular diagnostic products using PCR and next-generation sequencing (NGS) have significantly improved the understanding of molecular mechanism of hematological malignancies, leading to the right choice of molecular targeting drugs for precision therapy for the individual patients in clinic.
  • Infectious Disease
    Infectious Disease

About MEDx

Translational Medicine

MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.


Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient  stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.

view more >>

Events

Happy Chinese New Year
MEDx TMC | Happy Mid-Autumn Festival
MEDx Invite You: Medlab Asia & Asia Health on July 10th-12th, 2024

We are honored to invite you to participate in the Medlab Asia & Asia Health, which will take

MEDx TMC | Happy Father’s Day!
Dragon Boat Festival
Welcome to visit the MEDx Booth at Medlab Middle East 2024

Time:5-8 February, 2024Address:Dubai World Trade CentreMEDx Booth No: # Z2.H19We are honored

Meet MEDx at Medlab Middle East | Dubai 2024
On series |PIK3CA gene mutation and targeted therapy

Introduction The study of cancer has been extended from single genes to macrogenes, and from sing

Amgen’s Antibody Improves Overall Survival in Phase III Gastric Cancer Test

A combination of Amgen’s monoclonal antibody bemarituzumab and chemotherapy improved overall surviv

Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problems

Pfizer has terminated a Phase II trial that was evaluating its investigational fusion protein maplir

CAR T Guardrail Removal Earns FDA Favor with CGT Community

FDA leaders Marty Makary and Vinay Prasad have struck a tone of urgency when it comes to bringing in

Aggressive blood cancer: A key protein could pave the way for targeted therapies

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progre

Role of tumor microenvironment in nasopharyngeal carcinoma progression uncovered

A study led by clinician-scientists and researchers at the National Cancer Centre Singapore (NCCS) h

80% of colorectal cancers resist immunotherapy—this DNA treatment could help

A University of Alberta research team has identified a DNA structure that activates the immune syste

Gene mutation could be target for 'ultrapersonalized' therapies in colon cancer

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that c

Surviving breast cancer tied to lower Alzheimer's risk: Radiation therapy may offer short-term prote

Research led by Samsung Medical Center finds breast cancer survivors exhibit an 8% lower risk of Alz